부트리시란(Vutrisiran) 시장 보고서(2026년)

Vutrisiran is a small interfering RNA (siRNA) therapy used to treat hereditary transthyretin-mediated (hATTR) amyloidosis. It targets the transthyretin (TTR) gene, reducing the buildup of abnormal TTR protein that leads to polyneuropathy and organ damage. Vutrisiran helps slow the progression of the disease and enhances neurological function, mobility, and quality of life, offering the advantage of a longer dosing interval.

Vutrisiran belongs to several drug classes, including antisense oligonucleotides, nucleic acids, nucleotides, nucleosides, and others. Antisense oligonucleotides (ASOs) are synthetic short DNA or RNA strands designed to target specific mRNA sequences, thereby regulating gene expression. It can be administered via multiple routes, such as oral, injectable, and subcutaneous, and is intended for various patient populations, including pediatric, adult, and geriatric. Its distribution occurs through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

Tariffs have increased the cost of imported nucleic acid raw materials, oligonucleotide synthesis reagents, and specialized processing inputs used in siRNA drug manufacturing for the utrisiran market. These impacts are most pronounced in North America and Europe, where advanced RNA based therapeutics rely on global supply chains. Rising tariff related expenses have influenced manufacturing economics, pricing strategies, and capacity planning for siRNA therapies. This has affected commercialization timelines and supply availability. Positively, tariffs are encouraging localized biopharmaceutical production, expanded in region manufacturing capabilities, and stronger long term supply chain resilience.

The vutrisiran market research report is one of a series of new reports from The Business Research Company that provides vutrisiran market statistics, including vutrisiran industry global market size, regional shares, competitors with a vutrisiran market share, detailed vutrisiran market segments, market trends and opportunities, and any further data you may need to thrive in the vutrisiran industry. This vutrisiran market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vutrisiran market size has grown rapidly in recent years. It will grow from $0.67 billion in 2025 to $0.75 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to breakthrough siRNA approvals, unmet needs in hATTR amyloidosis, limitations of liver transplant options, expansion of orphan drug policies, improved genetic diagnosis.

The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.18 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to growing rare disease awareness, expansion of rna therapeutics pipeline, rising adoption of long-acting therapies, increased genetic screening, growth in specialty care centers. Major trends in the forecast period include growing adoption of rna interference therapies, increased focus on rare genetic disorders, expansion of long-interval dosing treatments, rising demand for targeted amyloidosis therapies, increased use of subcutaneous rna drugs.

The rising investment in research and development is anticipated to drive the expansion of the vutrisiran segment in the coming years. Research and development involves innovating and enhancing products, services, or processes through systematic investigation and experimentation. The surge in research and development (R&D) investment is fueled by government initiatives and funding, increasing healthcare and pharmaceutical demands, as well as sustainability and environmental considerations. R&D funding enables pharmaceutical firms to carry out clinical trials, demonstrating the drug's long-term efficacy and safety, which facilitates wider regulatory approvals. Moreover, advancements in RNA interference (RNAi) technology enhance the drug's accuracy, minimizing side effects and boosting patient uptake. For example, in April 2025, the Office for National Statistics, a UK government agency, reported that the UK government's net spending on research and development (R&D) reached approximately US $22.9 billion (£17.4 billion) in 2023, up from about US $20.0 billion (£16.1 billion) in 2022. Consequently, the growing investment in research and development is contributing to the expansion of vutrisiran.

Major companies in the vutrisiran sector are expanding its application to cardiomyopathy through regulatory approvals, such as supplemental indications for ATTR-CM, aiming to increase the patient population and enhance long-term value. A supplemental new drug application (sNDA) is a regulatory submission that allows an approved drug to be used for additional indications. For example, in March 2025, Alnylam Pharmaceuticals, a US-based biotech firm, obtained FDA approval for AMVUTTRA (vutrisiran) in adult patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), marking it as the first RNAi therapy approved for both polyneuropathy and cardiomyopathy forms of the condition. Consequently, the expansion into cardiomyopathy represents a significant trend fueling growth in the vutrisiran sector by extending its clinical reach and patient access.

In April 2024, Medison Pharma, an Israel-based pharmaceutical company, formed a partnership with Alnylam Pharmaceuticals Inc. to broaden the commercialization of RNAi therapeutics. The collaboration aims to improve global access to Alnylam's innovative RNAi treatments, particularly for patients with rare diseases, by leveraging Medison's integrated commercialization platform across multiple regions, including LATAM, APAC, and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that produces vutrisiran.

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vutrisiran market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vutrisiran market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vutrisiran Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses vutrisiran market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vutrisiran ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vutrisiran market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: RNA Interference (RNAi) Therapeutics; GalNAc-Conjugated Nucleic Acid Drugs; Synthetic RNA-Based Therapeutics
• 2) By Route Of Administration: Injectable; Subcutaneous
• 3) By Patient Demographics: Adult; Geriatric
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs; Gene-Silencing RNA Therapies
• 2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies; Hepatocyte-Targeted RNA Therapeutics
• 3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics; Long-Acting RNA Therapeutics
• Companies Mentioned: Alnylam Pharmaceuticals Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Vutrisiran Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Vutrisiran Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Vutrisiran Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Vutrisiran Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Growing Adoption Of Rna Interference Therapies
  • 4.2.2 Increased Focus On Rare Genetic Disorders
  • 4.2.3 Expansion Of Long-Interval Dosing Treatments
  • 4.2.4 Rising Demand For Targeted Amyloidosis Therapies
  • 4.2.5 Increased Use Of Subcutaneous Rna Drugs

5. Vutrisiran Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Genetic Disorder Centers
• 5.4 Retail Pharmacies
• 5.5 Homecare Patients

6. Vutrisiran Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Vutrisiran Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Vutrisiran PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Vutrisiran Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Vutrisiran Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Vutrisiran Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Vutrisiran Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Vutrisiran Market Segmentation

• 9.1. Global Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics
• 9.2. Global Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Injectable, Subcutaneous
• 9.3. Global Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adult, Geriatric
• 9.4. Global Vutrisiran Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
• 9.5. Global Vutrisiran Market, Sub-Segmentation Of RNA Interference (RNAi) Therapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies
• 9.6. Global Vutrisiran Market, Sub-Segmentation Of GalNAc-Conjugated Nucleic Acid Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics
• 9.7. Global Vutrisiran Market, Sub-Segmentation Of Synthetic RNA-Based Therapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics

10. Vutrisiran Market Regional And Country Analysis

• 10.1. Global Vutrisiran Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Vutrisiran Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Vutrisiran Market

• 11.1. Asia-Pacific Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Vutrisiran Market

• 12.1. China Vutrisiran Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Vutrisiran Market

• 13.1. India Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Vutrisiran Market

• 14.1. Japan Vutrisiran Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Vutrisiran Market

• 15.1. Australia Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Vutrisiran Market

• 16.1. Indonesia Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Vutrisiran Market

• 17.1. South Korea Vutrisiran Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Vutrisiran Market

• 18.1. Taiwan Vutrisiran Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Vutrisiran Market

• 19.1. South East Asia Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Vutrisiran Market

• 20.1. Western Europe Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Vutrisiran Market

• 21.1. UK Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Vutrisiran Market

• 22.1. Germany Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Vutrisiran Market

• 23.1. France Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Vutrisiran Market

• 24.1. Italy Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Vutrisiran Market

• 25.1. Spain Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Vutrisiran Market

• 26.1. Eastern Europe Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Vutrisiran Market

• 27.1. Russia Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Vutrisiran Market

• 28.1. North America Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Vutrisiran Market

• 29.1. USA Vutrisiran Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Vutrisiran Market

• 30.1. Canada Vutrisiran Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Vutrisiran Market

• 31.1. South America Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Vutrisiran Market

• 32.1. Brazil Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Vutrisiran Market

• 33.1. Middle East Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Vutrisiran Market

• 34.1. Africa Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Vutrisiran Market, Segmentation By Drug Class, Segmentation By Route Of Administration, Segmentation By Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Vutrisiran Market Regulatory and Investment Landscape

36. Vutrisiran Market Competitive Landscape And Company Profiles

• 36.1. Vutrisiran Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Vutrisiran Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Vutrisiran Market Company Profiles
  • 36.3.1. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Global Vutrisiran Market Competitive Benchmarking And Dashboard

38. Key Mergers And Acquisitions In The Vutrisiran Market

39. Vutrisiran Market High Potential Countries, Segments and Strategies

• 39.1 Vutrisiran Market In 2030 - Countries Offering Most New Opportunities
• 39.2 Vutrisiran Market In 2030 - Segments Offering Most New Opportunities
• 39.3 Vutrisiran Market In 2030 - Growth Strategies
  • 39.3.1 Market Trend Based Strategies
  • 39.3.2 Competitor Strategies

40. Appendix

• 40.1. Abbreviations
• 40.2. Currencies
• 40.3. Historic And Forecast Inflation Rates
• 40.4. Research Inquiries
• 40.5. The Business Research Company
• 40.6. Copyright And Disclaimer